Physician profile
Nick H Lee
NPI 1598881179
$65,189.38
in general payments reported to CMS, 2019-2025
68 companies · $6,176 in 2025
The $6,176 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $9,016 · 2021: $15K · 2022: $8,363 · 2023: $6,910 · 2024: $6,164 · 2025: $6,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,239.75 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18,276.49 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $12,048.58 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $3,385.80 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Abbvie INC. | $2,797.59 | 2019-2025 | |
| Amarin Pharma, INC. | $2,502.82 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,293.51 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,019.68 | 2019-2025 | Jardiance |
| Ibsa Pharma INC. | $1,827.88 | 2020-2025 | Tirosint, Licart, Tirosint |
| Pfizer INC. | $1,459.18 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,321.98 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $1,216.70 | 2019-2025 | Linzess |
| Novo Nordisk INC | $1,189.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Horizon Therapeutics Plc | $1,145.49 | 2020-2023 | Krystexxa |
| Lilly USA, LLC | $1,060.19 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $976.45 | 2019-2025 | Verquvo, Belsomra, Steglatro |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $886.63 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $777.78 | 2019-2025 | |
| Esperion Therapeutics, INC. | $774.53 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $718.14 | 2020-2023 | Xarelto |
| Ardelyx, INC. | $710.05 | 2023-2025 | Ibsrela |
| Eisai INC. | $538.08 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $475.87 | 2023-2025 | Voquezna |
| Allergan, INC. | $473.51 | 2019-2020 | |
| Almatica Pharma LLC | $381.94 | 2021-2025 | Loreev Xr, Teriparatide |
| Astellas Pharma US INC | $364.80 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $347.70 | 2020-2021 | |
| Radius Health, INC. | $340.76 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $299.92 | 2021-2023 | Cequa, Xelpros |
| Vivus LLC | $289.24 | 2022-2025 | Pancreaze |
| Merz North America, INC. | $264.43 | 2021-2023 | Xeomin |
| Lexicon Pharmaceuticals, INC. | $258.25 | 2024 | Inpefa |
| Aimmune Therapeutics, INC. | $257.19 | 2024-2025 | Zenpep, Vowst |
| Corium, LLC | $252.44 | 2022-2023 | Adlarity |
| Takeda Pharmaceuticals U.S.A., INC. | $243.70 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $232.79 | 2024-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $229.54 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Redhill Biopharma INC. | $219.75 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $202.57 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.20 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $182.01 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Regeneron Healthcare Solutions, INC. | $178.88 | 2025 | Dupixent |
| Genzyme Corporation | $174.07 | 2025 | |
| Scilex Pharmaceuticals INC. | $164.01 | 2019-2022 | |
| Ascend Therapeutics US, LLC | $152.02 | 2021-2023 | |
| Biogen, INC. | $122.57 | 2020-2022 | |
| Gilead Sciences, INC. | $98.43 | 2019-2023 | |
| Hikma Pharmaceuticals USA | $96.15 | 2019-2022 | |
| Lundbeck LLC | $95.30 | 2022-2024 | Rexulti |
| Genentech USA, INC. | $75.28 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $59.52 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $54.00 | 2023-2025 | Ingrezza |
| Nabriva Therapeutics, Plc | $47.09 | 2021-2022 | |
| Celgene Corporation | $43.16 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $39.10 | 2024-2025 | Rexulti |
| Eyevance Pharmaceuticals LLC | $38.74 | 2021 | |
| Exact Sciences Corporation | $37.22 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $36.16 | 2023 | Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $30.96 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $23.85 | 2022 | |
| Alkermes, INC. | $23.74 | 2022 | |
| Nestle Healthcare Nutrition INC. | $23.48 | 2020 | |
| Optinose US, INC. | $23.08 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.18 | 2021 | |
| Alk-Abello, INC | $21.31 | 2023 | Grastek, Odactra, Ragwitek |
| Dexcom, INC. | $18.27 | 2023 | Dexcom G6 Transmitter |
| Dermira, INC. | $17.74 | 2020 | |
| Cranial Technologies, INC | $17.71 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.20 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.